A recap of the top headlines from Contemporary OB/GYN in September 2026, spanning ACOG's respiratory vaccine guidance to the launch of the Missed & Dismissed podcast.
News|Articles|June 29, 2026
5 women's health FDA headlines you missed in Q2 2026
Author(s)Joshua Fitch, Senior Editor
Fact checked by: Benjamin P. Saylor, Tracy Ann Politowicz
A recap of the top FDA news stories covered by Contemporary OB/GYN in Q2 2026, spanning cervical cancer screening, menopause therapeutics, and antibiotic treatment for urinary tract infections.
Advertisement
Advertisement
We're officially at the halfway point of the year, and the past few months have delivered a steady stream of regulatory news for obstetricians-gynecologists (ob-gyns) to track. Below, the Contemporary OB/GYN team recaps some of the top FDA-related stories we covered last quarter, spanning cervical cancer screening, menopause therapeutics, and antibiotic treatment for urinary tract infections.
Related to this article
A recap of Contemporary OB/GYN's top FDA and regulatory news from September 2026.
A recap of the top videos and podcasts from Contemporary OB/GYN in September 2026, featuring expert interviews on salpingectomy, testosterone evidence, and more.
Anita Nelson, MD, discusses the FDA's approval extending etonogestrel implant use to 5 years and the new REMS certification clinicians must complete by February 23, 2027.
Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.
The FDA office of Women's Health and Center for Drug Evaluation and Research and hosting a public workshop with a focus on testosterone use in menopausal women.
Marla Shapiro, MDCM, explains how OPTION-VMS actigraphy data corroborated patient-reported sleep improvements with fezolinetant (Veozah) as early as week 4.
Soma Mandal, MD, is launching “Mind, Body, & the Pause: the Perimenopause and Beyond Series” on Contemporary OB/GYN, featuring specialists from across Hackensack Meridian Health.
Advertisement
Advertisement